Amarantus BioScience, Inc. (OTCQB:
AMBS), a biotechnology company discovering and developing treatments
and diagnostics for diseases associated with neurodegeneration and
apoptosis centered around its patented therapeutic protein
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF), today
published a blog post entitled “Q1: Setting the Stage for Growth in
2013” on TheChairmansBlog.com.
TheChairmansBlog.com is an exclusive online media publication that
enables key executive officers a unique platform to share insights
about their company and industry trends.
Amarantus’ President & CEO,
Gerald Commissiong, discusses the Company’s unique position in what
has been called “the year of the growth factor in Parkinson’s
Disease.” He writes about three key areas in which Amarantus plans
to make “solid progress in the first quarter” and how the Company
plans to maximize the value of MANF. Read the full blog post from
Gerald Commissiong on TheChairmansBlog.com.
About Amarantus BioScience Inc.
Inc. is a development-stage biotechnology company founded in January
2008. The Company has a focus on developing certain biologics
surrounding the intellectual property and proprietary technologies it
owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain
Injury and other human diseases. The Company owns the intellectual
property rights to a therapeutic protein known as
Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and
is developing MANF-based products as treatments for brain disorders.
The Company also is a Founding Member of the Coalition for Concussion
Treatment (#C4CT), a movement initiated in collaboration with Brewer
Sports International seeking to raise awareness of new treatments in
development for concussions and nervous-system disorders. For further
information, please visit www.Amarantus.com.
is an exclusive, online media publication where publicly and
privately held firms alike share insights about their companies and
industries. TheChairmansBlog.com enables upper tier management to
discuss issues that are of importance to their stakeholders,
shareholders, and interested parties in an informal environment. In
addition to management’s insightful blog posts,
TheChairmansBlog.com staff and aggregate partners contribute articles
on finance, technology, health and energy while providing updated
market trends news and information.
Forward Looking Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about the possible benefits of
MANF therapeutic applications and/or advantages presented by
Amarantus’ PhenoGuard technology, as well as statements about
expectations, plans and prospects of the development of Amarantus’
new product candidates. These forward looking statements are subject
to a number of risks, uncertainties and assumptions, including the
risks that the anticipated benefits of the therapeutic drug
candidates or discovery platforms, as well as the risks,
uncertainties and assumptions relating to the development of
Amarantus’ new product candidates, including those identified under
“Risk Factors” in Amarantus’ most recently filed Annual Report
on Form 10-K and Quarterly Report on Form 10-Q and in other filings
Amarantus periodically makes with the SEC. Actual results may differ
materially from those contemplated by these forward-looking
statements Amarantus does not undertake to update any of these
forward-looking statements to reflect a change in its views or events
or circumstances that occur after the date of this presentation. This
press release does not represent an offer to buy or sell securities.
Leave a comment...